Skip to main content
. Author manuscript; available in PMC: 2016 Oct 25.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2016 May 28;96(2):362–371. doi: 10.1016/j.ijrobp.2016.05.026

Table 2. Characteristics of patients who had a posttreatment neck dissection.

Characteristic p16 positive (n=69) p16 negative (n=30) P
Assigned treatment .39*
 SFX + cisplatin 39 (56.5) 14 (46.7)
 AFX-C + cisplatin 30 (43.5) 16 (53.3)
Age (y) .93
 Median (range) 55 (38-66) 55 (37-71)
Sex 1.00*
 Male 63 (91.3) 27 (90.0)
 Female 6 (8.7) 3 (10.0)
Race .06*
 White 62 (89.9) 22 (73.3)
 Non-white 7 (10.1) 8 (26.7)
Zubrod performance status .36*
 0 47 (68.1) 17 (56.7)
 1 22 (31.9) 13 (43.3)
Smoking history: pack-years (n=59) (n=22) <.001
 Median (range) 10.8 (0-152) 38.5 (0-100)
Primary site .40*
 Oropharynx, NOS 10 (14.5) 5 (16.7)
 Tonsillar fossa, tonsil 30 (43.5) 14 (46.7)
 Base of tongue 28 (40.6) 9 (30.0)
 Pharyngeal oropharynx 1 (1.4) 1 (3.3)
 Soft palate 0 (0.0) 1 (3.3)
T stage .08
 T2 31 (44.9) 9 (30.0)
 T3 22 (31.9) 9 (30.0)
 T4 16 (23.2) 12 (40.0)
N stage .71
 N1 2 (2.9) 2 (6.7)
 N2a 15 (21.7) 6 (20.0)
 N2b 26 (37.7) 7 (23.3)
 N2c 12 (17.4) 9 (30.0)
 N3 14 (20.3) 6 (20.0)
Primary disease status before neck dissection .09§
 Persistent abnormality 9 (13.0) 4 (13.3)
 No disease (cCR) 50 (72.5) 16 (53.3)
 Unknown/no assessment 10 (14.5) 10 (33.3)
Neck disease status prior to neck dissection .42§
 Persistent abnormality 38 (55.1) 13 (43.3)
 No disease (cCR) 18 (26.1) 8 (26.7)
 Unknown/no assessment 13 (18.8) 9 (30.0)
Interval between chemoRT and neck dissection (d) .95
 Median (range) 71 (17-154) 67 (35-169)

Abbreviation: cCR = clinical complete response. Other abbreviations as in Table 1.

Values are number (percentage) unless otherwise noted.

*

Fisher exact test. Primary site is tested as tonsil or base of tongue versus others.

Wilcoxon rank-sum test.

A pack-year is defined as the equivalent of smoking one pack of cigarettes a day for 1 year.

§

Chi-squared test.